<DOC>
	<DOCNO>NCT00406393</DOCNO>
	<brief_summary>The study design phase III , randomize , open label , multicenter , prospective , comparative trial sirolimus tacrolimus versus tacrolimus methotrexate graft-versus-host disease ( GVHD ) prophylaxis human leukocyte antigen ( HLA ) -matched , relate , peripheral blood stem cell transplantation individual hematologic cancer . Participants stratify transplant center randomly assign sirolimus/tacrolimus tacrolimus/methotrexate arm 1:1 ratio .</brief_summary>
	<brief_title>Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate Preventing Graft-Versus-Host Disease ( GVHD ) ( BMT CTN 0402 )</brief_title>
	<detailed_description>BACKGROUND : Stem cell transplantation standard therapy acute chronic leukemia myelodysplastic disorder . A common problem may occur stem cell transplant condition know GVHD . The purpose study compare two combination medication see well prevent GVHD . The combination medication study : - Sirolimus tacrolimus - Methotrexate tacrolimus Doctors want know one combination well result . DESIGN NARRATIVE : Participants receive one two conditioning regimen describe protocol , discretion transplant physician . The transplant physician must choose among regimen prior participant 's assignment GVHD prophylaxis treatment . Conditioning regimen vary center , participant center . Stem cell donor donate peripheral blood stem cell accord local institutional practice . Peripheral blood stem cell manipulate T-depleted prior administration . Standard post-transplant care administer . Participants randomly assign one two GVHD prophylaxis regimens followed endpoint interest . Participants follow 114 day post-randomization evaluation primary endpoint , additional follow-up 2 year transplantation evaluation secondary endpoint .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>6/6 HLAmatched sibling , define Class I ( HLAA B ) serologic type ( high resolution ) Class II ( HLADRBI ) molecular typing , willing donate peripheral blood stem cell , meet institutional criterion stem cell donation . The donor must medically eligible donate stem cell , accord individual transplant center criterion . Pediatric patient pediatric sibling donor anticipate suitable leukapheresis candidate eligible . Karnofsky performance status least 70 % Lansky performance status least 70 % participant le 16 year old For participant le 18 year old , willing able take oral medication , per treat physician 's recommendation Prior allogeneic autologous transplant use hematopoietic stem cell source Seropositive human immunodeficiency virus ( HIV ) Uncontrolled bacterial , viral , fungal infection ( currently take medication progression clinical symptom ) Pregnant ( positive serum human chorionic gonadotropin [ Î²HCG ] test ) breastfeeding within 4 week study entry Kidney function : serum creatinine outside normal range age , measure creatinine clearance le 50 mL/min/1.72m^2 within 4 week study entry Liver function : recent direct bilirubin , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) great two time upper limit normal within 4 week study entry Lung disease : adult , force vital capacity ( FVC ) force expiratory volume one second ( FEV1 ) less 60 % predict value ( correct hemoglobin ) ; child , overt hypoxemia , measure oxygen saturation le 92 % within 4 week study entry Cardiac ejection fraction le 45 % adult child , le 26 % shorten fraction child within 4 week study entry Cholesterol level great 500 mg/dL triglyceride level great 500 mg/dL treat , appropriate lipidlowering therapy within 4 week study entry Prior history allergy sirolimus Requires voriconazole time study entry Currently receive another investigational drug unless clear protocol officer protocol chair Participants history cancer , resect basal cell carcinoma treat carcinoma insitu . Cancer treat curative intent 5 year previously allow . Cancer treat curative intent le 5 year previously allow unless approve protocol officer protocol chair .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Chronic Myelogenous Leukemia</keyword>
</DOC>